AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer. Public release of a data set of this scale is unprecedented and is intended to help advance research into combination cancer therapy across the global scientific community.

About the Challenge

The AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge opened September 24, 2015. This Challenge will ask participants to develop predictive models of drug combination synergy across a large panel of cancer cell lines. In contrast to our previous DREAM Challenge on drug synergy, this Challenge will utilize a much larger drug screen with over 11,000 combinations. Multiple data types will be available to participants including single agent sensitivity, somatic mutations, copy-number alterations, DNA methylation, and gene expression.